Introduction: The Persistent Challenge of Chronic Allograft Rejection
Heart transplantation remains the definitive treatment for patients with end-stage heart failure. Despite significant advancements in surgical techniques and early-stage immunosuppression, the long-term survival of cardiac allografts is still hampered by chronic rejection and the cumulative toxicities of systemic immunosuppressive regimens. Conventional therapies often rely on high-dose, non-specific agents that can lead to opportunistic infections, malignancies, and metabolic complications. Consequently, there is an urgent clinical need for targeted strategies that can induce immune tolerance or long-term graft acceptance while minimizing systemic exposure.
A recent study published in Circulation (2026) by Che et al. introduces a groundbreaking approach to this problem. By targeting the specialized vasculature of the lymph nodes (LNs), specifically the High Endothelial Venules (HEVs), researchers have successfully delivered immunoregulatory payloads that promote graft acceptance and suppress chronic rejection in murine models.
